Merchant bank Burrill & Company and venture capital firms Clarus Ventures and Healthcap Ventures also invested in FerroKin BioSciences alongside MP Healthcare Venture Management.

MP Healthcare Venture Management (MPH), the corporate venturing unit of Mitsubishi Tanabe Pharma (MTP) and Mitsubishi Chemical, has invested as part of a consortium’s $12m backing for FerroKin BioSciences, a US-based biotechnology company developing treatments for iron overload in people’s blood.

Merchant bank Burrill & Company and venture capital firms Clarus Ventures and Healthcap Ventures also invested.

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?